News Releases

January 2022

January 10, 2022 1/10/2022 Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual JP Morgan Healthcare Conference

January 10, 2022 1/10/2022 Takeda to Acquire Adaptate Biotherapeutics

January 4, 2022 1/4/2022 Takeda to Present at The 40th Annual JP Morgan Healthcare Conference

December 2021

December 21, 2021 12/21/2021 Takeda Receives Complete Response Letter from the US FDA for TAK-721

December 17, 2021 12/17/2021 Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Chronic Pouchitis

December 8, 2021 12/8/2021 Publication of Data from SOLSTICE

December 7, 2021 12/7/2021 Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology Annual Meeting

November 2021

November 23, 2021 11/23/2021 Takeda’s LIVTENCITY (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies

November 1, 2021 11/1/2021 Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report with Tokyo Stock Exchange (TSE) in Line with Revised Corporate Governance Code and Published Corporate Governance related Documents on its website